# A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

> **NCT00583362** · PHASE2 · COMPLETED · sponsor: **Human Genome Sciences Inc., a GSK Company** · enrollment: 298 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Belimumab

## Key facts

- **NCT ID:** NCT00583362
- **Lead sponsor:** Human Genome Sciences Inc., a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-04
- **Primary completion:** 2016-02-23
- **Final completion:** 2016-02-23
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00583362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00583362, "A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00583362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*